The U.S. Drug Enforcement Administration (DEA), in partnership with the Department of Health and Human Services (HHS), has issued a Fourth Temporary Extension of the COVID-19 Telemedicine Flexibilities for the Prescription of Controlled Medications, extending the current telemedicine flexibilities through December 31, 2026. Telemedicine flexibilities regarding prescription of controlled medications include: A DEA-registered practitioner can prescribe a Schedule II-V controlled substance […]
DEA Grants Fourth Temporary Extension of Flexibilities for Tele-Prescribing Controlled Substances Through 2026
